Quantcast
Channel: ABN Newswire
Viewing all 12706 articles
Browse latest View live

FORUM: Explor Resources Inc. (CVE:EXS) Baffled..

$
0
0
I'm just baffled by the recent trading activity in Explor Resources Inc. (CVE:EXS) (FRA:E1H1) (OTCMKTS:EXSFF). Gold is in the USD$1,330 range, and Copper USD$3.11. Those prices, when considered in relation to the Timmins Porcupine Gold Deposit, and the Chester Copper Deposit in New Brunswick, should easily suggest a minimum $30-40million Market Cap.

Divide by 160 million shares, and the stock price even on those minimums is in a range of .18-.25CDN. Obviously, the numbers are not exact, but you get my point.

So, is it really shareholders driving the price backwards every time we brush double digits? Or, is something else going on? I've contended on a number of occasions that Explor, with its impressive array of promising gold exploration properties along the Porcupine Destor Fault, and in the Duparquet gold Camp, would be an outstanding takeover target? When I see the clever use of 'Dark Market' trading platforms regularly hiding trades from the retail buyers' eyes, it suggests, & promotes weakness in the stock.

Ultimately, when the culprits make their offer to the board at say .25/share, the vast collective shareholder base might be likely to take it. As gold moves into $1,400, & beyond, EXS/EXSFF/E1H1 will see $2-$3.00. I believe that's inevitable.

Apparently, drilling at East Bay will commence shortly. Geologists are in the process of finalizing the geochemistry, and geophysics associated with potential targets, and crew & equipment are being mobilized. Further, the M&A group are hard at work, and I expect they will be presenting some interesting proposals during the coming weeks.

NOTE: This forum commentary was published from a third party source. It has not been verified by the company.

Lithium Power International Ltd (ASX:LPI) Sale of Argentinian Lithium Project - Term Sheet Agreed

$
0
0
Lithium Power International Limited (ASX:LPI) (OTCMKTS:LTHHF) ("LPI" or "the Company") is pleased to provide an update on the planned sale of its Argentine lithium project situated in the Centenario salar.

Highlights

- Lithium Power International Limited has entered a conditional Term Sheet for the divestment of 100% of the Company's Centenario lithium project

- The Company's strategy is to focus resources on fast tracking the development of its large, high grade Maricunga lithium project in Chile

- The transaction has a total value of A$3.75m plus a 1.5% gross royalty and a backdated success fee

The Company has entered into a Term Sheet with Albertson Resources Pty Ltd ("Albertson") to dispose of 100% of the shares in Lithium Power International Holdings (Argentina) Pty Ltd, LPI's wholly-owned Australian subsidiary that holds LPI's interest in Centenario.

About the Centenario Properties

The Centenario project comprises of six tenements situated in the pro-mining province of Salta, Argentina. The Centenario project has a total land holding of 61.5km2 and was included in the Company Prospectus for LPI's listing on the Australia Security Exchange ("IPO") in June 2016.

Details of the Term Sheet

The Term Sheet grants Albertson exclusive due diligence rights for an agreed period of 45 days, in consideration of a non-refundable fee of $150,000, which was received by Company on 6 September 2017.

This binding Term Sheet is conditional on execution of a long-form sale agreement and satisfactory completion of due diligence by Albertson.

Upon the parties entering into long form agreements, the purchase price payable by Albertson will be:

- $850,000 cash payment on entry into the long form agreement;

- $2,750,000 on completion of the long form agreement, which is payable in cash or a minimum mix of 50% cash and shares;

- an additional success fee payable on finalisation of a maiden JORC resource; and

- a royalty of 1.5% on gross revenue from Centenario for a period of 20 years from completion of a definitive feasibility study.

Albertson will be responsible for costs associated with maintaining the Centenario project tenements in good standing from the date of entry into the long form agreement.

This divestment of the Centenario project will allow the Company to focus its resources on its world class Maricunga lithium project in Chile to accelerate the feasibility study underway and to fast-track the development timeline.

Lithium Power International's Chief Executive Officer, Martin Holland, commented:

"The Company has executed on its strategy to divest the Centenario project. This will allow the Company to place all our attention on fast tracking the Maricunga lithium project. We are pleased to have entered into a term sheet with Albertson Resources, and look forward to working together to complete the sale within the agreed timeline."

Martin C Holland - CEO
Lithium Power International
E: info@lithiumpowerinternational.com
T: +61-2-9276-1245
www.lithiumpowerinternational.com
Twitter: @LithiumPowerLPI

Big Un Ltd (ASX:BIG) September 2017 Quarter Market Update

$
0
0
Big Un Limited (ASX:BIG) (or 'the Company') is pleased to announce market guidance for Q1 FY18 following a continued strong start to the new financial year. Based upon the ongoing excellent performance from the BIG sales and production teams in August, BIG expects to achieve global cash receipts from customers in excess of $14m for Q1 (an increase of 449% from Q1 FY17 and a material increase of 12% on previous guidance). BIG will continue to maintain cashflow positive.

Outlook

Positive start to FY18

Commenting on the guidance, CEO Richard Evetz says, "We are continuing to experience strong demand for our video licensing products both domestically and internationally and anticipate that this trend will continue. The executive team are fully focused on delivering a balanced approach to expansion and cost management whilst capitalizing on market opportunity and maintaining shareholder value."

To view figures, please visit:
http://abnnewswire.net/lnk/81F6MO57

Sonia Thurston
Chief Communications Officer
E: ir@bigunlimited.com.au

XPED Ltd (ASX:XPE) Company Update

$
0
0
Xped Limited (ASX:XPE) ("Xped" or "the Company") is pleased to provide this market update.

Financial Position

Xped expects revenue to increase from approximately $1,200,000 in FY 2017 to in excess of $2,500,000 in FY 2018. This will largely be driven by the JCT Healthcare business with a number of well-advanced opportunities in the pipeline. The Company also anticipates strong revenue to commence from its partnership with Shenzhen Lenze Technology Co. LTD ("Lenze"). The Company is excited about the revenue potential in the Smart Home sector, with various Asian Based Telco opportunities in the pipeline. Xped looks forward to keeping the market informed of its progress.

As outlined in previous announcements the following non-recurring cash outlays impact FY 2018

- Q3 final acquisition payment for JCT Healthcare - $500,000

- Q3 L1 convertible note - $1,081,000 (Repaid 23/8/17)

- Q4 Penola remediation works - approximately $550,000

Expected non-operational inflows for FY 2018

- Sokoria project divestment USD$947,368 (end of FY 2018)

- Private Placement $3,000,000 (Occurred 25/08/17)

Cash on Hand as at 31 August 2017 $6,690,901

Cost Reduction Program

Over the last 9 months, significant resources have been employed ramping up internal engineering and outsourced engineering services to deliver the full IoT platform as quickly as possible to the market.

Xped has implemented a significant cost reduction program, which will largely be driven by the completion of some of the work in progress projects.

The Company has agreed with Cadmon Advisory Pty Ltd ("Cadmon") to cease retainer payments for the remainder of the General Corporate Advisory Mandate. The Board would like to acknowledge Cadmon's support of the Company's cost reduction activities. Cadmon will continue to provide corporate advisory services until 28 February 2018 at no additional cost.

The Company has undertaken a review of all costs to identify savings opportunities. This has resulted in a reduction in ongoing spend on contractors and consultants.

An independent remuneration review undertaken for the board has resulted in executive directors agreeing to reduce their remuneration package and together with other announced and impending actions will result in savings of $725,000 for this financial year.

The board's immediate strategy is addressing the cash burn and to focus on identifying products and opportunities that can be prioritised to generate income in the short term.

For more information:
Contact Xped Limited
T: +61-3-9642-0655
F: +61-3-9642-5177
E: info@xped.com
www.xped.com 

Corporate Enquiries:
Cameron Low
T: +61-3-9225-5474
E: ir@xped.com

Impact Minerals Limited (ASX:IPT) Major Shareholder to Increase Stake to 10%

$
0
0
Impact Minerals Limited (ASX:IPT) is pleased to announce that it has completed the placement of the remaining $0.9 million of shortfall from the Company's recent SPP (as defined below) to one of its major shareholders, who will consequently increase its relevant interest in the Company to 10%. The Company has now placed all of the shortfall from the SPP with total funds raised exceeding $2.9 million.

- Major shareholder takes Placement of final $0.9 million of Shortfall from the recent Share Purchase Plan to increase holding to 10%

- Placement completes full subscription of the SPP

- Funds to be primarily used for the ongoing drill programme and resource work at the Commonwealth gold-silver-base metals project in New South Wales

- Supplementary Prospectus attached

Impact Minerals' Managing Director, Dr Mike Jones, said "We are very pleased to have had strong support from one of our German shareholders, a Frankfurt-listed company that has progressively built its stake in Impact over the past few years. As a result we have now placed all of the shortfall from the recent Share Purchase Plan and so are very well funded to continue our on-going drill programme at the emerging Silica Hill gold-silver discovery 100 km north of Orange in New South Wales".

Background to additional placement

On 15 May 2017, Impact Minerals Limited (ASX:IPT) issued a prospectus seeking to raise up to $4,001,400 through the offer of 222,300,000 Shares together with 333,450,000 free attaching Quoted Options by way of a Share Purchase Plan to existing Shareholders, and a Shortfall Offer to the general public (together the SPP).

The Company raised $1,073,971 under the SPP through the issue of 59,665,051 Shares and 89,497,590 free attaching Quoted Options, which was approved by Shareholders at a general meeting of the Company on 20 June 2017.

As announced to ASX on 31 August 2017, the Company received firm commitments from sophisticated and professional investors to raise $2,000,000 by the issue of a portion of the shortfall from the recent SPP, being 111,111,111 Shares and 166,666,667 free attaching Quoted Options (Placement).

The Company is now pleased to announce that it has received a firm commitment covering the total of the remaining shortfall from the SPP. The aggregate amount raised is $2,927,429, comprising the issue of 162,634,949 Shares and 243,952,410 free attaching Quoted Options.

The Shares and free attaching Quoted Options will be issued on the same terms and conditions as those under the SPP, being $0.018 for each Share, with three free attaching Quoted Options exercisable at $0.04 on or before 15 June 2020 for every two New Shares subscribed for.

The Company lodged a prospectus (Prospectus) with the Australian Securities and Investment Commission (ASIC) for the Placement on 31 August 2017. The attached Supplementary Prospectus has been lodged with ASIC today in order to amend the Prospectus to address the placement of the remaining shortfall from the SPP.

The Prospectus and Supplementary Prospectus have been lodged with ASIC for the purposes of section 708A(11) of the Corporations Act to remove any trading restrictions on the Shares and free attaching Quoted Options issued.

To view Supplementary Prospectus, please visit:
http://abnnewswire.net/lnk/ZG16EN39

Dr Michael G Jones
Managing Director
Impact Minerals Limited
T: +61-8-6454-6666
E: info@impactminerals.com.au

YPB Group Ltd (ASX:YPB) Share Placement Raises $2.575m

$
0
0
Brand Protection and Customer Connection solutions company YPB Group Ltd (ASX:YPB) is pleased to announce that it has raised $2.575m via a placement to sophisticated and institutional investors. The placement price was $0.04.

- YPB raises $2.575m at $0.04 per share

- Board and associates key supporters

- Strategic private investors with strong China links

The raise was primarily driven by existing supporters of the company including current and recently retired directors. Shareholders will be asked to approve the directors' subscriptions for the placement shares under ASX Listing Rule 10.11.1 at the next General Meeting of the company.

Also participating were new strategic investors with technology expertise and links in a range of industries in China. These investors intend to actively help YPB access key decision makers and secure business in potentially high value industries in China.

The funds raised will be used to execute the acquisition of Motif Micro and for general working capital purposes. Motif Micro is a revolutionary Anti-Counterfeit technology with literally extraordinary potential. The current plan is for the first commercial releases of the technology to occur in the first half of 2018.

YPB Executive Chairman John Houston said: "While disappointing to be raising equity with such a weak stock price, the strong support from current and recently retired directors demonstrates their optimistic view of the company's prospects. I thank all participants in the placement for their support and particularly welcome our new shareholders. The team is intent on kicking important goals over the remainder of 2017 to ensure the company becomes profitable and self-sufficient as soon as possible."

Mr. John Houston 
Executive Chairman
YPB Group Limited
T: +61-458-701-088 
E: john.houston@ypbsystems.com 

Mr. Gerard Eakin
Director
YPB Group Limited
T: +61-427-011-596
E: eakin@manifestcapital.com
W: www.ypbsystems.com

FINANCE VIDEO: Revolution Metals Ltd CEO Tim Mckinnon talks with Geologist Julian Malnic During Deep Ground Penetrating Radar Survey

$
0
0
Revolution Metals Ltd CEO Tim Mckinnon talks with Geologist Julian Malnic during a Deep Ground Penetrating Radar (DGPR) Survey in Northern New South Wales.

The DGPR Survey was conducted by Ultramag Geophysics led by Geophysicist Philip McClelland. The DGPR system comprises of a Teflon coated antenna array that is easily deployed in any terrain, including the 37 degree slopes of the highly mineralized gold resource within the Revolution Metals exploration licences at Dalmorton NSW.

Founded in 1988, Ultramag Geophysics is one of the leading companies in geophysical exploration and geo-tech engineering in Australia.

With a proven track record of driving innovation and investing in R&D, the company leads the technological curve to deliver to the market new surveying and radar technology that reduces significant costs and improves both quality and service.

Download the NSW Department of Trade and Investment Investor Sheet for Revolution Metals Ltd here:
http://abnnewswire.net/lnk/8J71VWY5

To view the video, please visit:
http://www.abnnewswire.net/press/en/89895/revmet

Revolution Metals Ltd
Tim Mckinnon
T: +61-2-8205-7339
WWW: www.revolutionmetals.com

Ultramag Geophysics Pty. Ltd.
T: +61-2-4948-8100
WWW: www.ultramag.com

YPB Group Ltd (ASX:YPB) Signs with iSynergi an Alibaba Global Service Partner

$
0
0
Brand Protection and Customer Connection solutions company YPB Group Ltd (ASX:YPB) is pleased to announce it has signed an MOU with iSynergi Solutions (http://www.iSynergi.com.au) to protect Australian food and consumer goods brands exporting to China on the Alibaba platforms such as Alibaba.com, 1688.com, Taobao & TMall Global.

- YPB signs MOU with Alibaba.com Global Service Partner to Protect and Connect Australian exporters to China

iSynergi Solutions is a Melbourne based digital marketing company and is an Alibaba.com Global Service Partner. The company uses its expertise in the China market and its relationship with Alibaba to streamline the process for Australian brands to sell on Alibaba platforms.

There is significant groundswell of activity and success in utilising Alibaba platforms. iSynergi and YPB are building on this momentum and are engaged with clients developing custom solutions to fight fakes and connect customers in markets such as wine, infant formula, skincare & vitamins.

Kevin Lee Managing Director of iSynergi said: "We are delighted to partner with YPB to protect the authenticity of Australian brands, which is highly important in cross-border trade for business owners' and consumers' peace of mind. iSynergi is dedicated to provide e-commerce and digital marketing solutions for Australian exporters to China by utilising our market expertise and deep knowledge of Alibaba's platforms. I see great opportunity for iSynergi and YPB to help more Australian exporters develop their brands overseas while protecting brand value and connecting directly to their customers".

YPB Executive Chairman, John Houston, said "iSynergi's expertise in the China e-commerce market and in particular via Alibaba's platforms not only offers valuable revenue opportunities for YPB but will facilitate the development of further relationships within the Alibaba ecosystem. It is an important and valuable step in the company's development".

Mr. John Houston 
Executive Chairman
YPB Group Limited
T: +61-458-701-088 
E: john.houston@ypbsystems.com 

Mr. Gerard Eakin
Director
YPB Group Limited
T: +61-427-011-596
E: eakin@manifestcapital.com
W: www.ypbsystems.com

SpeedCast International Ltd (ASX:SDA) Response to Media Article

$
0
0
Speedcast International Limited (ASX:SDA) (Speedcast) refers to the speculative media article in The Australian dated 8 September 2017 in relation to Speedcast retaining advisers to identify potential buyers for the business.

Speedcast is not actively seeking buyers for the business and is focussed on continuing the demonstrated strong operating performance across each of its key divisions. The company does from time to time receive approaches from third parties who seek to explore potential opportunities that may lead to the creation of shareholder value.

Speedcast will keep the market informed as required.

Ian Baldwin
CFO
Speedcast International Ltd
E: ian.baldwin@speedcast.com
T: +61-432-680-746

Tianmei Beverage Group Corporation Limited (ASX:TB8) Accelerating Marketing & Product Innovation

$
0
0
Tianmei Beverage Group Corporation Limited (ASX:TB8) ("Tianmei" or the "Company") today provides an update on the Company's business growth strategy, ahead of its annual general meeting today.

- Rapid sales and profit growth momentum to continue throughout the second half of the financial year

- Growth to be driven by significant investment into:

o Marketing of existing products and in-store promotion

o Market analysis of its sales in established store locations to determine sales efficiencies

o Research and development to advance its pipeline of new product innovation

- Tianmei is strategically positioned to become a leading enterprise in the large and growing Chinese drinking water industry

As announced in Tianmei's half year report, the Company has delivered strong growth across its water, marketing and channel distribution business. For the half-year to May 2017, the Company reported significant increases in revenue, and strong growth in its gross and net margins.

The Company expects to continue this rapid growth momentum throughout the remainder of the current financial year. Continued expansion of the franchise stores in China is expected, with additional stores coming online in neighbouring provinces in the coming months. This will expand the Company's reach in its primary market of China. It also reinforces the continued growth of our channel capability, adding to the Company's reach and stability as growth is achieved.

Furthermore, through the implementation of a strategic marketing plan and continuous research and development, Tianmei will maintain its growth and profitability momentum.

Accelerating Marketing Efforts to Drive Sales

To further boost sales of its existing products, Tianmei is focused on two key marketing strategies. Firstly, the Company will focus on the vigorous promotion of its four water dispenser products, two water purifiers and its beauty spray. The increase in promotional efforts and publicity via television advertising and print media, is expected to drive sales and expand the Company's market share considerably for each of these products.

The second component of Tianmei's enhanced marketing campaign aims to build its sales in its established network of partner retail stores. The Company is planning to invest in an increased program of in-store promotion of its products in selected sales territories.

In conjunction with its in-store promotional efforts, the Company will also conduct market analysis of its sales in established territories and store locations to determine the most efficient pathway to maintain the Company's growth momentum.

Product Range Expansion via Ongoing R&D

Product innovation continues to form a significant part of Tianmei's growth strategy. The Company has identified several markets that are ripe for new product innovation through research and development. A selection of the Company's innovation pipeline is detailed below.

- High-end drinking water - The packaged drinking water industry in China has evolved and is characterised by accelerating growth in the popularity of natural mineral water. This consumer market focuses heavily on the mineral content of products. Accordingly, Tianmei is accelerating its research and development investment to create a high-end drinking water product. This new product would signal the Company's entry into the high-end water market.

- Expectant mothers' drinking water - Drinking water has been demonstrated as an important way for expectant mothers to supplement their diets with beneficial minerals and trace elements. Tianmei is progressing its research and develop plans to create a natural mineral water product that contains a variety of minerals and trace elements that can help boost the immune system of pregnant women, as well as support the development and growth of their babies during pregnancy.

- Sports water - Tianmei is developing a dedicated sports water product that enhances the consumer's sports ability, alleviates fatigue and helps to quickly regulate the body's function, while increasing athletic endurance.

- Active, natural mineral water - The Company plans to develop an active water product. With an increasing consumer focus on water quality, the product will promote negative ion absorption, help purify the blood, as well as support blood flow and metabolism.

Director, Mr John Zhang commented:

"Tianmei's established channel marketing opportunities, along with our innovation pipeline, gives us a sound position in the significant and developing Chinese fast moving consumer goods market. Our enhanced marketing campaigns to promote our existing brands of specialty waters, coupled with our strong focus on innovation to bring new products to market, will help the Company protect and grow its market share and continue the sales growth it achieved in the first half of the financial year.

"Our financial numbers are very strong and encouraging. Compared with the same period last year, revenue from self-supporting products has increased by 186.5% and the revenue from channel promoting increased by 300%. Compared with last year, the Company's gross profit margin has increased by 281% and our net margin increased by 416% - which is a significant result. Tianmei is strategically positioned to become a best-in-class leading enterprise in the international drinking water industry."

For media enquiries:
Justin Kelly
Media and Capital Partners
T: +61-408-215-858
E: justin.kelly@mcpartners.com.au

Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis Ltd (ASX:PXS) in Debilitating Liver Disease NASH

$
0
0
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3) (see Note 1 below), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

- Boehringer Ingelheim commences Phase II program of investigational drug candidate BI 1467335 acquired from Pharmaxis with a 12 week Phase IIa proof of clinical principle study in non-alcoholic steatohepatitis (NASH)

- New study underscores Boehringer Ingelheim's aspiration to deliver more first in class medicines with breakthrough potential for patients with cardio metabolic diseases

- Pharmaxis to receive EUR18 million milestone payment in a significant further endorsement of the company's ability to generate value from its early stage pipeline.

Non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in Western industrialized nations, and its more serious form NASH, is highly prevalent amongst patients with type 2 Diabetes. NASH is a major cause of liver fibrosis and cirrhosis and is an area of high unmet medical need with no treatments currently available. The high prevalence of type 2 diabetes and obesity is expected to make NASH one of the most common causes of advanced liver disorders in coming decades. 25% of the general adult population in the world has NAFLD and the prevalence of NASH has been found to range from 1.5% to 6.45% in current research, a number twice as high as 20 years ago.

In 2016 Boehringer Ingelheim obtained Fast Track Designation from the US Food and Drug Administration (FDA) for the development of BI 1467335 in NASH. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions which fill an unmet medical need. The designation provides opportunities for Boehringer Ingelheim to accelerate the development of this investigational drug candidate in NASH.

This Phase IIa trial is a multi-centre, double-blind design in 150 patients with clinical evidence of NASH. The primary objectives are to establish proof of clinical principle, investigate suitable dosing, and to evaluate the safety of BI 1467335. Patients will be randomized to either one of four dosages of BI 1467335 or to placebo for a 12-week treatment period. (see Note 2 below) A subsequent Phase IIb study will seek to confirm and extend these findings.

Dr. Christopher Corsico, Chief Medical Officer Boehringer Ingelheim Boehringer Ingelheim commented, "Advancing BI 1467335 into Phase II clinical research is important news for patients with NASH. Boehringer Ingelheim is committed to developing novel therapeutics designed to address unmet medical need and improve public health. Boehringer Ingelheim looks forward to further studying this novel compound in NASH patients".

Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for cardiometabolic disease patients. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes.

Pharmaxis CEO Mr. Gary Phillips said, "Pharmaxis selected Boehringer Ingelheim as our partner for PXS-4728A both because of the company's reputation as a leader in cardio metabolic research and development, and its outstanding track record in advancing external research. Today's announcement of the start of this Phase IIa clinical trial for NASH is excellent news and is very significant for Pharmaxis. It triggers the payment of an EUR18 million (A$27m) milestone to Pharmaxis and opens the path to a total of EUR195 million in milestone payments as the drug progresses through development and approval for this indication. The initiation of Phase II trials in a second indication later this year by Boehringer Ingelheim can bring the total potential value of the partnership with Boehringer Ingelheim to EUR418.5m (A$627m) plus sales milestones and high single digit earn-out payments on annual net sales."

About Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com

Notes:

1 Also known as vascular adhesion protein-1 (VAP-1) or semicarbazide-sensitive amine oxidase (SSAO)

2 http://clinicaltrials.gov/show/NCT03166735

Pharmaxis
Felicity Moffatt
Phone: +61-418-677-701
E: felicity.moffatt@pharmaxis.com.au

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Phone: +49 (6132) 77-90815
E: reinhard.malin@boehringer-ingelheim.com

Pharmaxis Ltd (ASX:PXS) Boehringer Ingelheim is Initiating Phase IIa Study for the Development of a New Treatment for Diabetic Retinopathy - a Leading Cause of Vision-Loss

$
0
0
Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN (Randomized study of Orally administered BI 1467335 in patients with Non-proliferative diabetic retinopathy without center-involved diabetic macular edema). This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH. BI 1467335 is an oral inhibitor of amine oxidase, copper containing 3 (AOC3) (see Note 1 below).

- Diabetic retinopathy (DR) is the second severe metabolic complication on top of non-alcoholic steatohepatitis (NASH) to be investigated for BI 1467335, which was acquired from Pharmaxis

- Pharmaxis will receive EUR10 million milestone payment when the first patient is dosed in this 2nd indication Phase IIa study.

- Boehringer Ingelheim's holistic cardio metabolism R&D strategy reaches from risk factors, like obesity to complications, like NASH and DR

Diabetic retinopathy (DR) is the leading cause of vision-loss in adults aged 20-74. It progresses from mild nonproliferative diabetic retinopathy to moderate and severe nonproliferative diabetic retinopathy (NPDR), characterized by retinal hemorrhages and vascular changes in the retina, to proliferative diabetic retinopathy (PDR), characterized by the growth of new blood vessels on the retina. Diabetic Macular Edema (DME), characterized by retinal thickening from leaky blood vessels, can develop at all stages of retinopathy. Of an estimated 285 million people with diabetes mellitus worldwide, approximately one third have signs of DR and of these, a further one third of DR is vision-threatening DR (severe NPDR, PDR and DME). (see Note 2 below)

The ROBIN trial is a Phase IIa multi-centre, double-masked design in 100 patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME). The primary objectives are to establish proof of clinical principle and to evaluate the safety and tolerability of BI 1467335. Patients will be randomized to either BI 1467335 or to placebo for a 12-week treatment period with an additional 12-week follow-up period afterwards. A subsequent Phase IIb study will seek to confirm and extend these findings. (see Note 3 below)

Dr. Christopher Corsico, Chief Medical Officer Boehringer Ingelheim said, "We are delighted to advance BI 1467335 into Phase II clinical research for a second indication, targeting a severe complication of diabetes. This is important news for the millions of patients threatened by losing their vision. Boehringer Ingelheim is committed to developing novel treatments designed to address unmet medical need and improve public health and looks forward to studying this novel compound in NPDR patients".

Gary Phillips, Pharmaxis CEO said, "I'm delighted that our partner Boehringer Ingelheim has decided to pursue a second indication for the drug acquired from Pharmaxis in 2015. It will be very rewarding for the Pharmaxis team to see another group of patients benefit from our initial work. The deal structure negotiated with BI recognised the potential that the drug had in multiple indications so expanding the development plan to include diabetic retinopathy as well as NASH means that we will receive a EUR10m milestone payment when the first patient is dosed in the DR Phase IIa study and that all the potential development milestones in the deal (EUR418.5m /A$625m), would be payable to Pharmaxis should both indications be approved. Our belief that Boehringer Ingelheim would be a company that sought to maximize the potential of the drug was central to our choice of partner and this latest development reaffirms that view."

About Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on http://www.boehringer-ingelheim.com
or in our annual report: http://annualreport.boehringer-ingelheim.com

Notes:

1 Also known as vascular adhesion protein-1 (VAP-1) or semicarbazide-sensitive amine oxidase (SSAO)

2 Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015;2:17

3 http://clinicaltrials.gov/ct2/show/NCT03238963

Pharmaxis
Felicity Moffatt
Phone: +61-418-677-701
E: felicity.moffatt@pharmaxis.com.au

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Phone: +49 (6132) 77-90815
E: reinhard.malin@boehringer-ingelheim.com

East Coles: 2017 'Best CFO's' S&P/ASX100 - Top 10 Finalists: APA, BTT, CTX, JBH, JHG, MQA, QUB, TPM, WES

$
0
0
The 2017 East Coles Corporate Performance Research has been completed and the Top 10 Finalists from the S&P/ASX100 for the 'Best CFO's' category for 2017 (not in ranked order) are: APA, BTT, CTX, JBH, JHG, MQA, QUB, TPM, WES. The Top 10 Finalists from the S&P/ASX101-200 for the 'Best CFO's' category for 2017 (not in ranked order) are: A2M, ALU, BAP, CGC, FPH, GUD, MTR, MIN, RWC, SDF.

Winners will be announced at the Awards Night which will be live streamed by Boardroom.media to a global audience. The 2017 East Coles Corporate Performance Awards Night will be held at the Ivy Ballroom on Thursday, 21 September. The incredibly talented electric violin artist Jane Cho will be performing on the night. Jane has also headlined world-class events for World Cup Racing, from Dubai through to London, and Australian Fashion Weeks. Entertainment will also include a fashion show with models kindly supplied by Bella Management, accessories from Oroton and jewellery from Paspaley.

All proceeds from the event will go to Transplant Australia. Transplant Australia is a national charity representing transplant recipients, donor families, living donors and all those touched by organ and tissue donation and transplantation. Transplant Australia saves lives.

This prestigious annual event is voted on by over 50 prominent financial services organisations, where equities analysts from both fund managers and brokerage houses score the S&P/ASX200 stocks they cover across 25 categories. The scores are then used to create league tables, with the idea being to provide a feedback mechanism between the investment community and the S&P/ASX200 to enhance market efficiency.
 
----------------------------------------------------------------------
S&P/ASX100 TOP 10 FINALISTS - 2017 AWARDS (not in ranked order)  

Category                                             Stock 

Best CFO                                         APA GROUP (ASX:APA) 
Best CFO                  BT INVESTMENT MANAGEMENT LIMITED (ASX:BTT) 
Best CFO                          CALTEX AUSTRALIA LIMITED (ASX:CTX) 
Best CFO                                  JB HI-FI LIMITED (ASX:JBH) 
Best CFO                         JANUS HENDERSON GROUP PLC (ASX:JHG) 
Best CFO                       MACQUARIE ATLAS ROADS GROUP (ASX:MQA) 
Best CFO                             QUBE HOLDINGS LIMITED (ASX:QUB) 
Best CFO                        RAMSAY HEALTH CARE LIMITED (ASX:RHC) 
Best CFO                               TPG TELECOM LIMITED (ASX:TPM) 
Best CFO                                WESFARMERS LIMITED (ASX:WES) 
----------------------------------------------------------------------
S&P/ASX101-200 TOP 10 FINALISTS - 2017 AWARDS (not in ranked order) 

Category                                             Stock 

Best CFO                       THE A2 MILK COMPANY LIMITED (ASX:A2M) 
Best CFO                                    ALTIUM LIMITED (ASX:ALU) 
Best CFO                                    BAPCOR LIMITED (ASX:BAP) 
Best CFO                      COSTA GROUP HOLDINGS LIMITED (ASX:CGC) 
Best CFO    FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (ASX:FPH) 
Best CFO                           G.U.D. HOLDINGS LIMITED (ASX:GUD) 
Best CFO                              MANTRA GROUP LIMITED (ASX:MTR) 
Best CFO                         MINERAL RESOURCES LIMITED (ASX:MIN) 
Best CFO            RELIANCE WORLDWIDE CORPORATION LIMITED (ASX:RWC) 
Best CFO                           STEADFAST GROUP LIMITED (ASX:SDF) 
---------------------------------------------------------------------- 
S&P/ASX100 TOP 10 FINALISTS - 2017 AWARDS (not in ranked order) 

Category                                             Stock 

Best Investor Relations               BHP BILLITON LIMITED (ASX:BHP) 
Best Investor Relations           CALTEX AUSTRALIA LIMITED (ASX:CTX) 
Best Investor Relations                        CSL LIMITED (ASX:CSL) 
Best Investor Relations                      GOODMAN GROUP (ASX:GMG) 
Best Investor Relations          JANUS HENDERSON GROUP PLC (ASX:JHG) 
Best Investor Relations                 OIL SEARCH LIMITED (ASX:OSH) 
Best Investor Relations         RAMSAY HEALTH CARE LIMITED (ASX:RHC) 
Best Investor Relations              SUNCORP GROUP LIMITED (ASX:SUN) 
Best Investor Relations                 WESFARMERS LIMITED (ASX:WES) 
Best Investor Relations        WESTPAC BANKING CORPORATION (ASX:WBC)  
---------------------------------------------------------------------- 

A note about Transplant Australia

Transplant Australia saves lives

Transplant Australia exists to enrich and celebrate life. Our vision is for Australia to lead the world in organ and tissue donation and transplantation - saving lives, improving quality of life and providing much needed care and support.

Our members share a special bond, having all been touched in some way by transplantation. They include those awaiting transplantation, donor families, living donors, transplant recipients, and the doctors, nurses and coordinators working in the organ and tissue donation and transplantation sector. While they have their own unique story to tell, they are part of a team that serves to celebrate and cherish the greatest gift of all - life itself.

A note about East Coles technology

Gordon Cairns Chairman of Origin Energy and Woolworths stated: "The East Coles Corporate Performance platform provides a powerful set of strategic analytics and investor tools which are not available elsewhere. It should be a critical component of every Board's decisionmaking process".

Nick Coles, Managing Director
East Coles Australia
M: +61-417-697-745
Lin: http://au.linkedin.com/in/nickcoles
E: nick.coles@eastcoles.com.au

Rebecca Thompson, Advisory Board
East Coles Australia
M: +61-416-079-329
Lin: http://www.linkedin.com/in/rebecca-thompson-86b55a1a/ 
E: rebecca.thompson@eastcoles.com.au
T: +61-2-8006-5088

Queensland Bauxite Ltd (ASX:QBL) Approval of Environmental Authority for the MDL Work Program

$
0
0
The Board of Queensland Bauxite (ASX:QBL) is delighted to announce that, after providing the Department of Natural Resources and Mines (DNRM) and the Department of Environment and Heritage Protection (DEHP) further information and responding to the Departments' queries, Mineral Development License (MDL) approval has been progressed for the South Johnstone Bauxite Project at Camp Creek in Queensland with the important decision received today from the DEHP to approve the amendment to our previous Environmental Authority (EA), to allow for the work programme intended under the MDL.

The EA permit now allows the company to undertake development work as per the intended MDL work programme (subject to MDL grant) in addition to the previously approved exploration activities in the South Johnstone region. The EA amendment approval decision follows on from receiving an assessment level decision earlier this year. The board and management of QBL believe that this EA permit is the last hurdle and paves the way for a decision on the MDL grant in the coming weeks.

As mentioned in the June Quarterly Report, a marketing agency has been signed up to assist in the process of obtaining sales agreements with bauxite refineries. Further, an agreement document (corporate offer to sell bauxite) has been signed with this ore marketing agency. This agency is currently working towards enabling a Sales and Purchase Agreement with a bauxite refinery in regards to the South Johnstone bauxite ore.

The next stage in the project, is to wait for the decision on the MDL grant while still working towards Mining Lease (ML) applications to allow for mining of all the identified bauxite ore resources at Camp Creek.

The bauxite mineralisation at South Johnstone being close to surface and right off the main highway adjacent to port, close to the Asian markets, means that the Company's capital and operational costs are estimated to be of the lowest cost bauxite projects. As previously reported in the Company's released scoping study, capital expenditure is expected to be only approximately $5 million, and operating expenditure is expected to be only AUD$20.87 per tonne FOB Mourilyan Harbour. For the full summary of the scoping study please see the announcement released by the Company on 29 December 2014 which can be accessed using the following link:

http://abnnewswire.net/lnk/N7TH05FJ

The operational results from the working of the MDL will be a key part of the overall strategy to develop an export operation in a staged development of South Johnstone that allows for long term mining and export on a prospect by prospect basis at low cost within the entire project area.

The DNRM and the DEHP are departments of the Queensland Government. The DNRM is responsible for regulating Queensland's water, land, mineral and energy resources. The DEHP is responsible for protecting the state's natural environment and historic places. For further information on these Government Departments see links: http://www.dnrm.qld.gov.au
and http://www.ehp.qld.gov.au

Queensland Bauxite Ltd
Tel: +61-2-9291-9000

For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au

Impact Minerals Limited (ASX:IPT) Extension of Prospectus Offer

$
0
0
Impact Minerals Limited (ASX:IPT) advises that the Closing Date of the Offer under the prospectus dated 31 August 2017 (Prospectus) has been extended. The Offer will now close at 5.00pm WST on Monday, 11 September 2017.

The revised indicative timetable in relation to the Offer is as follows:

Event: Closing Date of Offer (5.00pm WST)
Date: Monday, 11 September 2017

Event: Issue of Offer Securities
Date: Tuesday, 12 September 2017

Event: Quotation of Offer Securities
Date: Wednesday, 13 September 2017

Event: Despatch of Holding Statements for Offer Securities
Date: Thursday, 14 September 2017

Dr Michael G Jones
Managing Director
Impact Minerals Limited
T: +61-8-6454-6666
E: info@impactminerals.com.au

White Cliff Minerals Ltd (ASX:WCN) Rights Issue - Shares Issued

$
0
0
White Cliff Minerals Ltd (ASX:WCN) advises that it has issued for 468,596,860 ordinary shares at an issue price of $0.002 upon completion of the Company's 1-for-2 non-renounceable rights issue. This issue has raised $937,194 in working capital that will be used to further advance the Company's exploration projects both in the Kyrgyz Republic and Australia.

The Company now has 2,348,074,584 ordinary shares on issue.

The Company has previously been advised by the rights issue underwriter, Gleneagle Securities Nominees Pty Ltd, that it has received commitments from its clients to place all the shortfall shares, being 471,142,147 ordinary shares. The allocation of the shortfall shares will occur in accordance with the rights issue timetable and, if fully completed, will raise an additional $942,284 in working capital.

Todd Hibberd
Managing Director
T: +61-8-9321-2233
E: info@wcminerals.com.au
W: www.wcminerals.com.au

Luke Forrestal
Media + Capital Partners
M: +61-411-479-144
E: luke.forrestal@mcpartners.com.au

Ardiden Ltd (ASX:ADV) Seymour Lake Drilling and Development Update

$
0
0
Lithium and graphite explorer Ardiden Limited (ASX:ADV) is pleased to provide an update on drilling and pre-development activities at its 100%-owned Seymour Lake Lithium Project in Ontario, Canada.

The second diamond drilling rig now on site at South Aubry prospect with drilling to commence shortly as Ardiden continues to progress project evaluation, permitting and key stakeholder consultations

HIGHLIGHTS:

- Successful community consultation meeting held with Whitesand First Nation, MNDM and environment consulting group DST.

- Initial stages of Feasibility Study underway with commencement of Environmental Baseline Study.

- Further stakeholder meeting planned for late November, as the visas to Canada were delayed for Yantai Jinyun technical representatives.

- Second diamond drill rig and geological team now on site at the South Aubry prospect.

The Company is pleased to report that it recently held a very successful initial community consultation meeting with the Whitesand First Nation, the Ministry of Northern Development and Mining ("MNDM") and other interested parties. Ardiden is extremely encouraged by the discussions, with all parties acknowledging the proposed aggressive development timeline and pledging their support for the advancement of the Seymour Lake Lithium Project into commercial production.

One of the main prerequisites to move the project to the next stage is the completion of a Feasibility Study ("FS"), which also requires the completion of an Environmental Baseline Study ("EBS") for required approvals. Ardiden has engaged DST Consulting Engineers ("DST"), from Thunder Bay, to complete the EBS as they have detailed knowledge of the area and have already established a working relationship with the Whitesand First Nation.

DST have already commenced the first stage of the EBS program, with various data collection programs and surveys underway including but not limited to ground water analysis, rainfall, site access, topography, flora and fauna. Subject to the ongoing results and provincial and federal environmental requirements, Ardiden expects the EBS to be completed by late 2018.

Representatives from the Company's Chinese strategic partner, Yantai Jinyuan Mining Machinery Co., Ltd ("Yantai"), were not able to attend the community consultation meeting with the Whitesand First Nation due to delays in receiving their travel visas. As a result, a further stakeholder meeting has now been planned for late November, so that Yantai can meet with the various stakeholders and undertake a site visit.

Following the successful community consultation meeting with Whitesand First Nation, representatives from the MNDM and DST also undertook a site visit to the North Aubry prospect at the Seymour Lake Lithium Project to obtain a better understanding of the project for the completion of the feasibility work and development requirements.

During the community consultation meeting, a variety of objectives were discussed including access to the market. Whitesand First Nation representatives highlighted the potential use of the historical Ferland Railway Station as a means to access the railway network to transport the future lithium concentrate to end-users.

With the permission of the Whitesand First Nation elders, Ardiden conducted a brief site visit to the Ferland Railway Station and, subject to further and more detailed analysis during the feasibility program, this railway site could provide the Company with a strategic advantage by dramatically reducing transport time and costs, given its location just 3.5km south of project.

Due to a number of unforeseen delays, the second diamond drill rig has now arrived at the Seymour Lake Lithium Project. The Company's drilling and geological teams are completing preparations and are due to commence drilling shortly at the South Aubry prospect, which will be followed by additional drilling at the Central Aubry prospect.

The Company looks forward to providing further updates as they come to hand.

To view tables and figures, please visit:
http://abnnewswire.net/lnk/DD7K3I43

Investors:
Brad Boyle
Ardiden Ltd
Tel: +61-8-6555-2950

Media:
Nicholas Read
Read Corporate
Mobile: +61-419-929-046

Ardiden Ltd (ASX:ADV) Ardiden Ltd Webcast

$
0
0
Diversified minerals explorer and developer Ardiden Limited (ASX:ADV) provides the opportunity to listen to an audio webcast with Brad Boyle, CEO and Executive Director in a presentation titled:

"ARDIDEN LTD SEYMOUR LAKE UPDATE"

The webcast will be made available on the Boardroom Media website. To listen to the webcast, copy the following details into your web browser:

http://www.abnnewswire.net/lnk/D8RK407N

The presentation details are as follows:

Speaker: Brad Boyle, Executive Director

Investors:
Brad Boyle
Ardiden Ltd 
Tel: +61-8-6555-2950 

Media:
Nicholas Read 
Read Corporate
Mobile: +61-419-929-046

OtherLevels Holdings Ltd (ASX:OLV) Wins Leading U.K. Publisher

$
0
0
OtherLevels Holdings Limited (ASX:OLV) ("OtherLevels") has announced that it has signed a leading UK publisher.

The publisher, is an iconic name in the U.K. market, and is the leader in its sector.

OtherLevels will initially work with the publisher to deploy two message types - web push and interstitials.

OtherLevels digital marketing strategists will work with the in-house team to drive increased conversion activity, helping to turn unknown site visitors into known readers.

Lance Standing, OtherLevels General Manager UK and EMEA, commented, "We are very excited to be working with another leading U.K. publisher. Using our Intelligent Messaging for Conversion capabilities we will work with the in-house team, to convert more unknown site visitors into known readers, hence increasing conversion, and reducing the need and cost of re-targeting unknown on-line visitors."

Media Enquiries: 
E: media@otherlevels.com

Regeneus Ltd (ASX:RGS) Edison Investment Report Issued

$
0
0
The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Please contact or connect with Regeneus via social media platforms below if you'd like further information.

To view the Edison Report, please visit:
http://abnnewswire.net/lnk/ZT58EC4E

Sandra McIntosh
Company Secretary and Investor Relations
 
Tel: +61 2 9499 8010
Fax: +61 2 9499 8020
Mob: +61 450 253 059
Email: investors@regeneus.com.au
Viewing all 12706 articles
Browse latest View live




Latest Images